Daily Stock Analysis, CRBP, Corbus Pharmaceuticals Holdings Inc, priceseries

Corbus Pharmaceuticals Holdings Inc. Daily Stock Analysis
Stock Information
Open
4.41
Close
4.55
High
4.65
Low
4.41
Previous Close
4.44
Daily Price Gain
0.11
YTD High
9.11
YTD High Date
Feb 15, 2019
YTD Low
4.18
YTD Low Date
Nov 14, 2019
YTD Price Change
-2.00
YTD Gain
-30.53%
52 Week High
9.11
52 Week High Date
Feb 15, 2019
52 Week Low
4.18
52 Week Low Date
Nov 14, 2019
52 Week Price Change
-1.63
52 Week Gain
-26.38%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 10. 2017
7.10
Mar 14. 2017
8.90
21 Trading Days
25.36%
Link
LONG
Aug 23. 2017
6.15
Sep 7. 2017
7.10
10 Trading Days
15.43%
Link
LONG
Jan 26. 2018
8.90
Jan 30. 2018
9.43
2 Trading Days
5.93%
Link
LONG
Aug 24. 2018
5.00
Sep 6. 2018
5.26
8 Trading Days
5.25%
Link
LONG
Oct 17. 2019
4.93
Oct 30. 2019
5.20
9 Trading Days
5.45%
Link
Company Information
Stock Symbol
CRBP
Exchange
NasdaqGM
Company URL
http://www.corbuspharma.com
Company Phone
617-963-0103
CEO
Yuval Cohen
Headquarters
Massachusetts
Business Address
100 RIVER RIDGE DRIVE, NORWOOD, MA 02062
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001595097
About

Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Its produc, JBT-101 is a novel synthetic oral endocannabinoid-mimetic drug that is intended to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. The company was founded in December 2013 and is headquartered in Norwood, MA.

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.